ASCO: Updated targeted therapy clinical trials results continue to show improved outcomes for advanced colorectal and bladder cancers
Updated results from two MD Anderson clinical trials presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting indicate improved outcomes for cancer patients with specific gene mutations when treated with targeted therapies. Targeted therapies from both the BEACON CRC and the BLC2001 clinical trials resulted in FDA approvals of treatments for subsets of patients with advanced colorectal and bladder cancers....
ASCO: Emerging targeted therapies show signs of clinical activity across multiple cancer types
Julia Pitts tried all the standard treatment options with her local physicians after she was diagnosed with metastatic uterine cancer in 2015...
ASCO: Studies show advances in treatment and understanding of BRCA-associated and triple-negative breast cancer
Mutations in the BRCA 1 or 2 genes significantly increase an individual’s risk of developing breast cancer, as well as several other cancer...
Larotrectinib shows marked responses with NTRK gene fusions, limited response in non-fusion mutations
In an analysis of three clinical trials, the targeted therapy larotrectinib resulted in a 79% overall response rate and median overall survival of 44.4 months in adult and pediatric patients with advanced cancers and NTRK gene fusions, regardless of cancer type. In contrast, those with other mutations in NTRK that were not gene fusions saw only a 1% overall response rate of median overall survival of just 10.7 months, highlighting the...
Triple-negative breast cancer clinical trial allies with community oncologists
Triple-negative breast cancer (TNBC) is an aggressive disease that makes up roughly 15% to 20% of breast cancer diagnoses. Standard chemotherapy...
Metastatic cells, mechanisms of drug resistance identified for triple-negative breast cancer
Researchers at The University of Texas MD Anderson Cancer Center have discovered important mechanisms of drug resistance and metastasis in...
Combination therapy key in two studies of blood cancers likely to relapse
Results from two MD Anderson studies demonstrated the significance of combination therapy in follicular lymphoma and chronic lymphoblastic...
Lung cancer targeted therapy hits common HER2 variants across cancers
Building upon the foundational discovery that the targeted therapy poziotinib is a potent and selective inhibitor of specific EGFR and HER2...
Breast, ovarian cancer trials find targeted therapies provide benefit over chemotherapy
Results from two The University of Texas MD Anderson Cancer Center-led clinical trials indicate that targeted therapies led to significant...
Innovative combination clinical trial results revealed at ASCO
MD Anderson researchers will present clinical trial results of promising combination therapies for a variety of cancers at the 2019 American...